Viewing StudyNCT03773302

Home Icon Home Search Icon Search Alerts Icon Stocks Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs eRecord Icon eRecord
Main Search All Studies All Organizations Report Bug
View Study With Definitions
Ignite Creation Date: 2024-05-06 @ 12:30 PM
Last Modification Date: 2024-10-26 @ 12:59 PM
Study NCT ID: NCT03773302
Status: TERMINATED
Last Update Posted: 2024-05-08
First Post: 2018-12-10
Brief Title: Phase 3 Study of BGJ398 Oral Infigratinib in First Line Cholangiocarcinoma With FGFR2 Gene FusionsTranslocations
Sponsor: QED Therapeutics Inc
Organization: QED Therapeutics Inc
Overview Dates Organization Conditions Design Enrollment Locations Outcomes

Conditions & Keywords Data

Conditions:
Name
FGFR2 Gene Mutation
Advanced Cholangiocarcinoma
Keywords:
Name View
BGJ398 View
cholangiocarcinoma View
unresectable cholangiocarcinoma View
metastatic cholangiocarcinoma View
fibroblast growth factor receptor inhibitor View
FGFR2 View
FGFR2 gene fusionstranslocations View